COMMUNIQUÉS West-GlobeNewswire

-
Cannabix Technologies Annual General and Special Meeting Results
25/07/2025 -
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
25/07/2025 -
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
25/07/2025 -
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
24/07/2025 -
Cytokinetics to Announce Second Quarter Results On August 7, 2025
24/07/2025 -
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer
24/07/2025 -
Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq
24/07/2025 -
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025
24/07/2025 -
Treace to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025 -
Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025 -
OPKO Health to Report Second Quarter 2025 Financial Results on July 31
24/07/2025 -
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
24/07/2025 -
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
24/07/2025 -
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025 -
CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
24/07/2025 -
RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025 -
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
24/07/2025 -
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
24/07/2025 -
The Ensign Group Reports Second Quarter 2025 Results; Raises Annual Earnings and Revenue Guidance
24/07/2025
Pages